Pathological complete response in early-stage HER-2 positive breast cancer patients, receiving neoadjuvant chemotherapy/trastuzumab, in a single breast unit in Johannesburg

Simple item page
dc.contributor.authorBellomo, Alessandro N
dc.date.accessioned2024-03-12T07:46:18Z
dc.date.available2024-03-12T07:46:18Z
dc.date.issued2024
dc.descriptionA research report submitted in partial fulfilment of the requirement for the degree of Master of Medicine (MMed) to the Faculty of Health Sciences, University of the Witwatersrand, School of Anatomical Sciences, Johannesburg, 2023
dc.description.abstractBackground HER-2 positive breast cancers receiving neoadjuvant therapy containing Trastuzumab show higher rates of pathological complete response, correlating to better clinical outcomes. Trastuzumab is not available in the neoadjuvant setting in the public healthcare system in South Africa. Methods This study evaluated factors affecting pCR in early-stage HER-2 positive breast cancers. We retrospectively analysed data of 102 patients with early-stage HER-2 positive breast cancer who completed neoadjuvant trastuzumab/chemotherapy. The cohort was analysed for total pCR and looked at factors that may affect pCR (tumor size, menopausal status, hormone receptor status, Ki-67 levels, and nodal status). Results The pCR rate for the entire cohort was 58.82%. Factors associated with a higher pCR were ER receptor status (ER negative= 82.05%, ER positive 44.4%, P<0.00018), PR receptor status (PR negative=75.41% vs PR positive 34.15%, P< 0.00003). The Ki67 <14% was 46.15%, Ki67 14-30% was 51.11% and Ki67> 30% was 70.45% (P<0.037). Univariate analysis showed a significant difference in pCR relating to ER/PR/HER-2 grouping (ER/PR positive= 63.64%, Triple positive= 34.15%, Enriched= 82.05%; P<0.00007). Conclusions: This data highlights the importance of characterising the different subtypes of HER-2 positive early breast cancers and the association with pCR, in keeping with the international guidelines. Higher pCR rates were attained in HER-2 enriched subtypes. Currently, in South Africa, trastuzumab is not readily available in the public healthcare sector. This study emphasizes the need for trastuzumab to be made available to all patients with HER-2 positive breast cancers in the neoadjuvant setting in South Africa.
dc.description.librarianTL (2024)
dc.facultyFaculty of Health Sciences
dc.identifier.urihttps://hdl.handle.net/10539/37813
dc.language.isoen
dc.schoolSchool of Anatomical Sciences
dc.subjectBreast cancers
dc.subjectNeoadjuvant
dc.subjectChemotherapy/trastuzumab
dc.subject.otherSDG-3: Good health and well-being
dc.titlePathological complete response in early-stage HER-2 positive breast cancer patients, receiving neoadjuvant chemotherapy/trastuzumab, in a single breast unit in Johannesburg
dc.typeDissertation
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
WITS MMED Abstract.pdf
Size:
54 KB
Format:
Adobe Portable Document Format
Download
Thumbnail Image
Name:
WITS MMED Corrections.pdf
Size:
362.91 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.43 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
ETD Collection